Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013

Mary Gleeson, Eliza A. Hawkes, Clare Peckitt, Andrew Wotherspoon, Ayoma Attygalle, Bhupinder Sharma, Yong Du, Mark Ethell, Mike Potter, Claire Dearden, Alan Horwich, Ian Chau, David Cunningham

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)


Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003–2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.

Original languageEnglish
Pages (from-to)1805-1813
Number of pages9
JournalLeukemia and Lymphoma
Issue number8
Publication statusPublished - 3 Aug 2017
Externally publishedYes


  • Follicular lymphoma
  • high-grade transformation
  • rituximab era
  • stem-cell transplantation

Cite this